Preliminary Data from Two Clinical Trials with ADC Candidates were Presented Orally at the 2025 ASCO Annual Meeting
SHANGHAI and CHICAGO, June 5, 2025 /PRNewswire/ -- The 2025 ASCO Annual Meeting is taking place in Chicago, US, from May 30 to June 3. Duality Bio (HKEX: 9606.HK) presented the preliminary data of two clinical trials, HER3 ADC candidate DB-1310 and...
Innovent's IBI363 (PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) Receives Second NMPA Breakthrough Therapy Designation for Immuno-resistant Squamous Non-Small Cell Lung Cancer
SAN FRANCISCO and SUZHOU, China, June 5, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of...
Witness the power of images to change the world: The First SmallRig Awards Announce 22 Global Winners
SHENZHEN, China, June 4, 2025 /PRNewswire/ -- The 2025 International Image Culture Week kicked off in Shenzhen with the highly anticipated 2025 SmallRig Awards Ceremony, where 22 prestigious awards were presented to exceptional global creators. The...
"Xiamen Day" Successfully Held at Expo 2025 Osaka China Pavilion, Fostering a New Era of Multifaceted Collaboration
OSAKA, Japan, June 3, 2025 /PRNewswire/ -- From May 31 to June 1, 2025, "Xiamen Day" captivated audiences at the China Pavilion of Expo 2025 Osaka. Under the theme "Facing the Sea, Flowers Blooming in Four Seasons" and guided by the principles of...
Investbanq Reflects on the Road Ahead After a Successful Meet the Drapers Finale
SINGAPORE, June 3, 2025 /PRNewswire/ -- As the season seven finale of the global startup reality show Meet the Drapers aired, Singapore-based fintech startup Investbanq took a moment to reflect on what the experience meant—not just as a recognition...
2025 ASCO ｜Oral Presentation: Disitamab Vedotin Achieves Stellar Efficacy as First-Line Therapy for HER2-Expressing Locally Advanced or Metastatic Gastric Cancer
YANTAI, China, June 3, 2025 /PRNewswire/ -- On June 2 (Chicago time), in an oral presentation at the 2025 ASCO Annual Meeting, Dr. Lin Shen from Beijing Cancer Hospital presented the results of a Phase 2 clinical study conducted in China evaluating...
ASCO 2025 Oral Presentation: Innovent Biologics Announces Updated Data of IBI363 (First-in-class PD-1/IL-2α -bias Bispecific Antibody Fusion Protein) from Phase 1 and 2 Clinical Studies on Immunotherapy-treated Advanced Malignant Melanoma
SAN FRANCISCO and SUZHOU, China, June 1, 2025 /PRNewswire/ -- Innovent Biologics, Inc (Suzhou) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of...
Mabwell Receives NMPA Approval for Albipagrastim alfa for Injection (MAILISHENG)
SHANGHAI, May 30, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced that Albipagrastim alfa for Injection (trade name: MAILISHENG, R&D code: 8MW0511) developed by its...
"Made-in-Shanghai" Takes China-chic Brands and Shanghai's Fashion Ecosystem to Osaka
OSAKA, Japan, May 29, 2025 /PRNewswire/ -- More than a fascinating array of creative exhibits, pop-up stores and twin-city forums, "Made-in-Shanghai" is an international showcase of Shanghai's fashion ecosystem. On May 21st to 25th, the sixth...
Experimental Drug Development Centre Granted U.S. FDA Fast Track Designation for Antibody-Drug Conjugate EBC-129 to Treat Pancreatic Ductal Adenocarcinoma
EBC-129 is the first made-in-Singapore antibody-drug conjugate (ADC) to enter clinical development. It selectively targets a tumour-specific N-glycosylated epitope on both CEACAM5 and CEACAM6. The Fast Track Designation highlights the potential of...